Silence Therapeutics plc (SLN)

NGM – Real Time Price. Currency in USD

14.53

-0.19 (-1.29%)

Market open: Aug 12, 2026, 10:51 AM EDT

14.75

+0.03 (0.20%)

Previous after-hours: Aug 11, 2026, 7:53 PM EDT

12.08.2026

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS. In addition, Silence.

11.08.2026

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company's plan to advance a quarterly dosing regimen into Phase III.

10.08.2026

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

10.08.2026

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States. The proposed offering is a public offering registered under th.

10.08.2026

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics plc (NASDAQ:SLN) stock is trading higher on Monday after the company reported positive topline outcomes from its Phase 2 SANRECO study assessing divesiran for polycythemia vera. It is a rare, slow-growing blood cancer where the bone marrow makes too many red blood cells.

10.08.2026

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). The 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously (s.c.) ev.

10.08.2026

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial at the European Hematology Association (EHA) 2026 Annual Congress in J.

Videos

No Data

There is no data to display

Press releases

12.08.2026

Silence Therapeutics plc (SLN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Silence Therapeutics plc (SLN)

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Videos

No Data

Press releases

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Videos

No Data

Press releases

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Search stocks

Silence Therapeutics plc (SLN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Silence Therapeutics plc (SLN)

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Videos

No Data

Press releases

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Videos

No Data

Press releases

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results